Company intelligence / Profile preview

Sylentis

Ownership: Private
Employees: ~16
Development stage: Phase 3

Overview

Sylentis has advanced its lead candidate tivanisiran to Phase III clinical trials for dry eye disease. Another candidate, SYL1801 targeting neovascular AMD, is in Phase II. The company has demonstrated promising preclinical and clinical results using its proprietary RNAi technology to silence disease-causing genes primarily in ophthalmology. It also participates in the IPCEI Med4Cure initiative to develop sustainable oligonucleotide manufacturing and therapies targeting rare diseases.[1][4][5]

Therapeutic areas: OphthalmologyRare Diseases
Modalities: siRNA (small interfering RNA)Oligonucleotide-based drugs
Industry: Biotech

Drug pipeline

6 assets

tivanisiran

5 more assets in the full pipeline.

Request access →

Partnerships

IPCEI Med4Cure consortium partners via the SYOLIGO project; additional CDMO partnerships possible but not specified by name.[5]

Beyond the preview

Go deeper on Sylentis.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sylentis.

Explore the full profile